PathologyLabTraining

Antibody Screening and Identification: The IAT, Clinically Significant Antibodies and Safe Compatibility

13 min read · Published: 2025-01-08 · Updated: 2026-06-08

The antibody screen is the quiet workhorse of pre-transfusion testing: most are negative, but the small proportion that are positive can mean the difference between a safe transfusion and a fatal haemolytic reaction. For the NHS biomedical scientist (BMS), screening and identifying red cell alloantibodies is not a mechanical exercise; it is about understanding what the indirect antiglobulin test (IAT) is detecting, deciding whether an antibody actually matters clinically, and then selecting blood that will survive in the patient. This guide covers the antibody screen, the identification panel, the IAT, the concept of clinical significance, and how findings translate into compatible units, all framed for current 2026 UK practice.

Why we screen: the alloantibody problem

A small but clinically important minority of patients carry "atypical" or irregular red cell alloantibodies, produced after previous exposure to foreign red cell antigens through transfusion, pregnancy or transplantation. Unlike the naturally occurring ABO antibodies, these are unpredictable: a patient who grouped and crossmatched without incident last year may have formed a new antibody since.

The antibody screen exists to find these antibodies before blood is issued, so that antigen-negative, compatible units can be selected. Missing a clinically significant antibody can result in an immediate or delayed haemolytic transfusion reaction (HTR), and, in females of childbearing potential, haemolytic disease of the foetus and newborn (HDFN). Under the British Society for Haematology (BSH) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories, antibody screening is a mandatory part of pre-transfusion testing because it is more sensitive and reliable than relying on the crossmatch alone.

The indirect antiglobulin test (IAT): the core technique

The IAT is the central serological method in immunohaematology. It detects IgG antibodies that bind to red cell antigens at 37°C but do not directly agglutinate the cells. The principle is two-stage:

1. Sensitisation: patient plasma is incubated with reagent red cells at 37°C. Any IgG present attaches to the corresponding antigens, but the cells stay in suspension because IgG molecules are too small to bridge the gap between cells. 2. Detection: anti-human globulin (AHG) reagent is added. This "antiglobulin" binds the attached IgG (and, if polyspecific, complement) on adjacent cells, cross-linking them into a visible agglutinate.

Because the IAT mimics what happens in vivo when incompatible cells are transfused, it is the most clinically relevant antibody-detection method. BSH guidance identifies a low ionic strength solution (LISS) IAT as the most suitable approach for detecting clinically significant antibodies, owing to its speed, sensitivity and specificity. Most UK laboratories deliver the IAT using column agglutination technology (CAT) — gel or glass-bead cards — on automated platforms, although tube and solid-phase methods remain in use. Whatever the platform, the method must be locally validated before routine use.

What the antibody screen requires

The screen tests patient plasma against a panel of fully characterised reagent red cells, by IAT. To detect the antibodies that matter, the reagent cells themselves must express the right antigens. BSH guidance sets out clear minimum requirements:

The emphasis on homozygous (double-dose) expression reflects dosage: some antibodies, classically anti-Jkᵃ and anti-Jkᵇ in the Kidd system, react far more strongly with cells carrying a double dose of the antigen and may be missed against heterozygous cells. The high sensitivity to Kidd antibodies is deliberate, because they are a well-recognised cause of delayed haemolytic transfusion reactions. If the screen is negative, no further serological work is usually needed. If any cell reacts, the laboratory must move to identification.

Antibody identification: working out the specificity

A positive screen tells you an antibody is present; it does not tell you what it is. Identification uses a larger panel of group O reagent red cells of known, comprehensive phenotype, tested against the patient's plasma by IAT (and often additional techniques). The principle is one of inclusion and exclusion: by comparing the pattern of positive and negative reactions against the panel's antigen grid, the analyst matches the reactions to a single specificity (or mixture) and excludes the others.

BSH guidance specifies the minimum panel composition for reliable work:

A single panel may not resolve a mixture of antibodies, so BSH strongly recommends keeping a selection of two different panels, which increases the chance of identifying a mixture while excluding additional clinically significant specificities. An enzyme-treated panel is also valuable: enzymes such as papain enhance reactions of Rh, Kidd and P1 antibodies while destroying Duffy (Fyᵃ/Fyᵇ), MNS (M, N, S) and others — a useful tool for separating an antibody mixture.

A robust identification follows a disciplined sequence:

1. Confirm the reaction pattern is reproducible and review the autocontrol or direct antiglobulin test (DAT). 2. Cross out (exclude) specificities against non-reacting cells that carry homozygous expression of the relevant antigen. 3. Identify the candidate specificity that fits all reacting cells. 4. Apply the "rule of three" / statistical confidence: confirm the pattern against sufficient antigen-positive and antigen-negative cells. 5. Phenotype the patient for the corresponding antigen — a patient with a genuine anti-K should type as K-negative. A patient who types positive for the antigen cannot have made the alloantibody, prompting a rethink. 6. Exclude additional underlying antibodies, especially where reactions vary in strength.

If the patient has a previously known alloantibody, every new sample must be fully re-tested to exclude further alloantibodies, because additional specificities can develop over time.

Clinically significant versus clinically insignificant antibodies

Not every antibody causes harm. A clinically significant antibody is one capable of causing an HTR and/or HDFN — typically an IgG antibody that reacts at 37°C by IAT and can shorten the survival of transfused antigen-positive cells. A clinically insignificant antibody (often IgM, reacting only at lower temperatures and not by IAT at 37°C) does not destroy transfused cells and does not require antigen-negative blood. Getting this distinction right prevents both unsafe transfusion and the opposite error — unnecessary delay and wastage chasing antigen-negative units for a harmless antibody.

The table below summarises BSH guidance on the likely clinical significance of common specificities and the recommended approach to selecting red cells.

| Blood group system | Specificity | Likely clinically significant? | Red cell selection | |---|---|---|---| | Rh | Anti-D, -C, -c, -E, -e | Yes | Antigen negative | | Kell | Anti-K, -k | Yes | Antigen negative | | Kidd | Anti-Jkᵃ, -Jkᵇ | Yes | Antigen negative | | Duffy | Anti-Fyᵃ, -Fyᵇ | Yes | Antigen negative | | MNS | Anti-S, -s, -U | Yes | Antigen negative | | MNS | Anti-M (active at 37°C) | Yes | Antigen negative | | MNS | Anti-M (not active at 37°C), Anti-N | No | IAT crossmatch-compatible at 37°C | | Lewis | Anti-Leᵃ, -Leᵇ, -Leᵃᵇ | No | IAT crossmatch-compatible at 37°C | | P1PK | Anti-P1 | No | IAT crossmatch-compatible at 37°C | | Lutheran | Anti-Luᵃ | No | IAT crossmatch-compatible at 37°C | | H | Anti-HI (in A₁/A₁B patients) | No | IAT crossmatch-compatible at 37°C | | Diego | Anti-Wrᵃ | Yes | IAT crossmatch-compatible (low-frequency antigen) | | Any | Other antibody active by IAT at 37°C | Yes | Seek advice from the Blood Centre |

The key principle: where antigen-negative blood is recommended, it must also be IAT crossmatch-compatible. Where an antibody is insignificant, IAT crossmatch-compatible units issued and tested at 37°C are acceptable. Any new or unexpected specificity reacting at 37°C should be treated as significant until proven otherwise, with reference to a Blood Centre or red cell reference laboratory.

From identification to compatible blood

Once a clinically significant antibody is confirmed, selecting blood becomes a structured task:

This work must operate within an accredited quality framework. UK transfusion laboratories work to ISO 15189:2022 under UKAS, the Blood Safety and Quality Regulations enforced by the MHRA, and report serious events to SHOT (Serious Hazards of Transfusion) and the MHRA's SABRE system. Reagents, methods and the IAT itself are subject to internal quality control and UK NEQAS external quality assessment.

The crossmatch, electronic issue and sample timing

The final compatibility step depends on the antibody status. The IAT (serological) crossmatch — testing donor cells directly against patient plasma — is the default technique where antibodies are present or suspected, where there is no validated IT system, or where electronic issue is otherwise contra-indicated. It must be used if the patient's plasma contains, or has been known to contain, alloantibodies of likely clinical significance.

Electronic issue (EI) allows the LIMS to select and issue units without a serological crossmatch, but only when strict criteria are met, including:

Sample timing underpins all of this. Where a patient has been transfused or pregnant within the preceding three months, the sample must be no more than 3 days old at the time of transfusion, because a new antibody can appear quickly after a recent immunising event. Many laboratories accept a longer validity (commonly up to 7 days) only where there is no such history. For first-time patients, a second sample taken as an independent event is required to confirm the ABO group before group-specific blood is issued (the "two-sample rule"), unless secure electronic patient identification is in place.

Frequently Asked Questions

What is the difference between the antibody screen and the crossmatch?

The antibody screen tests patient plasma against two or three fully characterised reagent screening cells to detect any alloantibody. The crossmatch tests patient plasma directly against the actual donor units to be transfused. The screen is more sensitive for detecting antibodies because screening cells carry known homozygous antigen expression, whereas the IAT crossmatch confirms compatibility of the specific units being issued.

Why does the antibody screen use a minimum of two cells that are not pooled?

Two cells with complementary phenotypes (typically R₁R₁ and R₂R₂) ensure all common clinically significant antigens are represented. Cells are tested individually rather than pooled because pooling would dilute a weak antibody, potentially below the limit of detection. BSH guidance also requires homozygous expression of Kidd, Duffy and S/s antigens to capture dosage-dependent antibodies such as anti-Jkᵃ.

How do I know if an antibody is clinically significant?

In general, an antibody reacting by IAT at 37°C is treated as clinically significant because it can destroy transfused antigen-positive cells. Specificities in the Rh, Kell, Kidd, Duffy and Ss systems (and anti-M active at 37°C) are clinically significant. Antibodies such as anti-Leᵃ, anti-Leᵇ, anti-P1, anti-N and anti-M not active at 37°C are usually insignificant, but any unfamiliar 37°C-reactive antibody should be referred for advice.

Why give antigen-negative blood when the antibody is no longer detectable?

Alloantibody levels naturally fall over time and may become undetectable, but the immune system retains memory. If antigen-positive cells are transfused, an anamnestic response can rapidly regenerate the antibody and cause a delayed haemolytic transfusion reaction. For this reason, a historically identified clinically significant antibody mandates antigen-negative, IAT crossmatch-compatible units even on a currently negative screen.

What is electronic issue and who is excluded from it?

Electronic issue allows the LIMS to select and issue compatible red cells without a serological crossmatch, provided grouping and screening are fully automated, the current group matches the historical record, and the screen is negative. Patients with any current or historical clinically significant antibody are permanently excluded, and must instead receive antigen-negative units confirmed by IAT crossmatch.

What role does quality control play in the IAT?

For tube and microplate IAT, IgG-coated (sensitised) control cells are added to all negative tests to confirm the AHG reagent is active and the wash phase was adequate. The control cells must agglutinate; if they do not, free anti-IgG was neutralised by unwashed plasma, the result is invalid, and the test must be repeated in full. Reagents and methods are further monitored through internal QC and UK NEQAS external quality assessment.

Further training

For the wider context of laboratory quality, accreditation and diagnostic competence, start with the pillar guide to NHS Laboratory Training. To build the related skills that surround antibody work, see these sibling articles:

Related Articles